Wülfing, C <br/><br/>
[Therapy of hormone refractory prostate cancer: new standards, new trends].  [electronic resource] 

 -  Aktuelle Urologie  Aug 2005 
 - 342-8 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Review 
<br/><br/><label>ISSN: </label>0001-7868 
<br/><br/><label>Standard No.: </label>10.1055/s-2004-830209  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Clinical Trials, Phase I as Topic<br/>Clinical Trials, Phase II as Topic<br/>Clinical Trials, Phase III as Topic<br/>Diphosphonates--administration & dosage<br/>Docetaxel<br/>Drug Resistance, Neoplasm<br/>Endothelin Receptor Antagonists<br/>Humans<br/>Male<br/>Meta-Analysis as Topic<br/>Mitoxantrone--administration & dosage<br/>Mutation<br/>Oligonucleotides, Antisense--therapeutic use<br/>Patient Selection<br/>Prostatic Neoplasms--drug therapy<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Quality of Life<br/>Randomized Controlled Trials as Topic<br/>Receptors, Androgen--genetics<br/>Taxoids--administration & dosage<br/>Time Factors<br/>Trastuzumab